Loading company…
MagicRNA develops RNA medicines, vaccines and delivery technologies for cancer and other diseases.
Based in Shenzhen, China, MagicRNA develops mRNA drugs for gynecological diseases and urinary system tumors, as well as infectious disease vaccines, tumor vaccines and protein replacement therapies. Its platforms cover mRNA sequence design, synthesis and lipid nanoparticle delivery; its first tumor therapy, HN2201, completed preclinical development. Founded in 2021, the company raised Series B funding in August 2026, co-led by China International Capital Corporation and Kangjun Capital, with participation from China Development Bank Capital, Boc Private Equity Firm, SND Ventures Group, Guoshun Investment, IDG Capital, Nanling Fund, Huatai Zijin Investment, Sino Biopharmaceutical Limited and Goldport Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in